Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
See our 2012 Buyers Guide Digital Edition.
 
|
Four Out of Five BioSpain 2012 Participants Identified Genuine Business Opportunities
Publish date: Mar 5, 2013
PR Newswire MADRID, March 5, 2013
MADRID, March 5, 2013 /PRNewswire/ -- A survey reveals visitor satisfaction of 93%, while 97% would be interesting in attending future
editions of the fair. BioSpain 2012, held in Bilbao in September 2012, has strengthened
its position as the principal platform for creating business opportunities in Spain's biotechnology
sector. A survey by the organisation reveals that 77% of BioSpain 2012 participants identified genuine business opportunities
at the event. This aligns with the objectives established by the organisation, which aims for BioSpain to drive the industry
in the current adverse economic situation. As regards general satisfaction, 93% rated the event positively and 88% stated that it had met their expectations; networking
was the most highly-valued activity. In fact, partnering at this year's three-day event led to a record 2,775 one-on-one meetings,
making it the fifth-largest international event of its type in terms of networking. Moreover, 97% of those meetings are expected to lead to a second meeting at a later date. Partnering and one-on-one meetings
at BioSpain are increasingly viewed as positive because of the technology available to participants; this year more than 643
technologies and products were on offer (22% more than at the previous edition, in 2010). The survey also provides useful information regarding biotechnology firms' priorities in this adverse economic environment.
The main objective of 48% of BioSpain 2012 participants was to identify R&D collaboration opportunities. Other goals were
to attract potential clients (46%), learn about the latest trends and technology (32%) and study the competition (26%). With respect to the future, 97% of participants will consider attending the next edition of BioSpain in 2014 (venue to
be determined). Click on the link below for the survey results: http://www.asebio.com/documents/resultados_encuesta_para_web_asebio.pdf
Further information from:
SOURCE BioSpain 2012 Committee Organization
|
|
|
|
|
Facebook
Quizzes
